期刊
CLINICAL TRANSPLANTATION
卷 23, 期 1, 页码 140-145出版社
WILEY-BLACKWELL PUBLISHING, INC
DOI: 10.1111/j.1399-0012.2008.00953.x
关键词
cell-based immunotherapy; regulatory macrophage
资金
- European Commission)
- Deutsche Forschungsgemeinschaft [GE-1188/1-1]
Patient KW, a 36-yr-old male renal transplant recipient, received transplant acceptance-inducing cells (TAICs) as an adjunct immunosuppressive therapy. In the weeks post-transplantation, the patient's conventional immunosuppressive treatment was gradually minimized, such that, from the 21st wk post-transplantation onwards, the patient was stably maintained on tacrolimus monotherapy. Treatment with TAICs was without complication, both at the time of administration and in the four-yr follow-up period. It is concluded that the production and administration of TAICs to recipients of kidney transplants from deceased donors is technically feasible.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据